Alpha d_3-teva

Roman name

Alpha D_3 # -Teva

The composition and the form of

1 soft capsule jelatinova pink alfakalzidola contains 0.25 g; blistere in 10 pcs. , in a cardboard bundle one blister or polypropylene bottle 60 st.1 soft capsule jelatinova orange-2.4.3; blistere in 10 pcs. , in a cardboard bundle one blister.

Characteristics

Previously active metabolita D_3 vitamin.

Of drugs

Regulatory calzi-fosfornyi exchange, complementary deficiency of Vitamin D. Increases the absorption of calcium and phosphorus in the gut, their reabsorbqiyu in the kidneys increases bone mineralization, reduces paratireoidnyi hormone in the blood.

Pharmacokinetics

After intake of rapidly absorbed from the digestive tract. C_max plasma achieved through 8-18 hours Metabolised mainly in the liver during the active metabolite of vitamin D_3 - calzitriol less, in the bone. Not biotransformiroetsa in the kidneys (as opposed to natural vitamin D_3).

Clinical pharmacology

Restores calzievy positive balance in limestone malabsorbce by reducing the intensity rezorbtion bone, which helps to reduce the frequency of fractures. In kursovom use reduces bone and muscle pain associated with the violation of fosforno-calzievogo, improves coordination of movements.

Indications

Osteoporosis (incl. postmenopausny, senilny, steroidnyi); Osteodistrofia with chronic renal failure; Hypothetical, and psevdogipo- giperparatireoz (with the defeat of the bones); Rickets and osteomalacia of malnutrition or suction; Gipofosfatemiceski vitamin D-rezistennetary and psevdodefitsitny (vitamin D-zawisimy) rickets and osteomalacia; Falconi syndrome (hereditary kidney disorders with nefrocalzinozom, late rickets and adipozogenitalina underweight); kidney disorders.

Pregnancy and lactation

Application of pregnancy can be done only in absolute grounds (if the effect on the mother than the potential risk to the fetus). During treatment should abandon breastfeeding.

Contraindications

Hypersensitivity, gipercalziemia, giperfosfatemia (except when such gipoparatireoze) gipermagniemia, intoxication vitamin D, breast-feeding.

Side-Effects

From the metabolic : rarely gipercalziemia very rarely, a slight increase LPVP plasma; In patients with acute violations of the kidney may develop Giperfosfatemii.so part of the intestine : anorexia, nausea, vomiting, indigestion, pain in the stomach, dry mouth, feeling discomfort epigastrii, constipation or diarrhoea, rarely, a slight increase in ALT, AST Plazme.so in the central nervous system : rarely weakness, fatigue, headache, dizziness, Sonlivosti.so the musculoskeletal system : Moderate pain in the muscles, bones, Sustawah.prochie : tachycardia, allergic reactions (skin rashes, itching of the skin).

Patient interaction

Together with the use of drugs naperstanki increased risk of arrhythmia. Preparations trigger enzymes mikrosomalnogo oxidation (barbiturates, anti-convulsants, etc.), reduce the bioavailability Alpha D_3 -teva (requires a larger dose). Kolestiramin, colestipol, sukralfat, antatsida, drugs on the basis of albumin, mineral oils reduce inflammatory alfakalzidola. Joint application with antatidami lacsativodializ and increase the risk gipermagniemii. Appointment with drugs calcium and tiazidnami dioretikami, as well as preparations containing vitamin D or its derivatives, increases the risk gipercalziemii.

Overdosing

Symptoms : a Gipercalziemii.lechenie : Removal of the preparation. In the early stages of acute overdose - washing stomach and / or the appointment of mineral oil (may reduce intake and increase product launch with the faeces). In severe cases it is necessary to / in a izotoniceski solution of sodium chloride, a loop dioretikov, glucocorticoids.

Precautions

Be wary appoint people who are vulnerable to the gipercalziemii particularly affected urolithic Boleznew.v period of preparation should be regularly (at least once in three months) to control the level of calcium in the plasma and urine, monitor the therapeutic effect and, if necessary, adjust the dose in order to avoid the development and gipercalziemii Gipercalziurii.pri the biochemical signs of normalcy in bone structure (normalization of the alkaline phosphatase in the plasma) to the decrease dosage, thus avoiding gipercalziemii development. Gipercalziemia gipercalziuria or can be adjusted by removing the drug and reduce consumption of calcium to normalize its concentration in the plasma. Generally, this period is one week. The therapy may be continued from the last half prinimavcheixia doses.

Dosing and Administration

Inside, once a day (morning). The duration of the physician individually and depends on the nature of the disease and the effectiveness of therapy. In some cases, drug use throughout Jizni.vesroslam : when rahite and osteomalation (from exogenous vitamin D endocrine diseases or long protivosudorojna therapy), 1-3 µ g / day; Gipoparatireoze with 2-4 µ g / day; In osteodystrophies (with chronic renal failure), and 2 g / day; with Fanconi syndrome and kidney azidoze, 2-6 µ g / day; in gipofosfatemicescom rahite and osteomalation, 4-20 µ g / day; with osteoporosis-0.5-1 g / sut. Treatment should start with a minimum of the dose monitoring once a week the level of calcium and phosphorus plasma. Dose can be increased to 0.25 g / day to stabilize the biochemical Pokazatelei.detam weighing less than 20 kg-on 0.01 µ g / kg / day, the body weight of 20 kg or more, 1.0 g / day (except in the case of renal osteodystrophies-dose 0,04-0,08 g / kg / day).

Storage conditions

kaps.jelatin. : At room температурекапс.жела��ин. : At room temperature no higher than 25 ° C

Shelf life

kaps.jelatin. : 3 and

Directory → Metaboliki → Corrector metabolism of bone and cartilage tissue → Alpha d_3-teva